Tryptophan is an essential amino acid that can be metabolised through different pathways, a major route being the kynurenine pathway. The fi rst enzyme of the pathway, indoleamine-2,3-dioxygenase, is strongly stimulated by infl ammatory molecules, particularly interferon gamma. Thus, the kynurenine pathway is often systematically up-regulated when the immune response is activated. The biological signifi cance is that 1) the depletion of tryptophan and generation of kynurenines play a key modulatory role in the immune response; and 2) some of the kynurenines, such as quinolinic acid, 3-hydroxykynurenine and kynurenic acid, are neuroactive. The kynurenine pathway has been demonstrated to be involved in many diseases and disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, AIDS dementia complex, malaria, cancer, depression and schizophrenia, where imbalances in tryptophan and kynurenines have been found. This review compiles most of these studies and provides an overview of how the kynurenine pathway might be contributing to disease development, and the concentrations of tryptophan and kynurenines in the serum, cerebrospinal fl uid and brain tissues in control and patient subjects.
Introduction
Tryptophan is one of the 9 essential amino acids that the human body is incapable of synthesizing and thus, has to be obtained through external sources. Once absorbed by the body, tryptophan travels around the periphery circulation either bound to albumin or in free form, the two states existing in equilibrium, with the former accounting for up to 90%. 1 However, tryptophan can only be transported across the blood brain barrier in its free form by the competitive and non-specifi c L-type amino acid transporter. 2 Once in the central nervous system (CNS), tryptophan acts as a precursor to various metabolic pathways. This versatility results in different end-products, such as protein, serotonin and kynurenines. 3 In both the peripheral and central systems, the kynurenine pathway represents a major route for the metabolism of tryptophan.
Following the kynurenine pathway ( Fig. 1 ), tryptophan is oxidized by cleavage of the indole-ring, initiated either by tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO-1) or IDO-2, a newly discovered IDO related enzyme. [4] [5] [6] [7] TDO resides primarily in the liver and is induced by tryptophan or corticosteroids. 4 IDO-1, on the other hand, is the predominant enzyme extra-hepatically and can be found in numerous cells, including macrophages, microglia, neurons and astrocytes. [8] [9] [10] [11] It is up-regulated by certain cytokines and infl ammatory molecules, such as lipopolysaccharides, amyloid peptides and human immunodefi ciency virus (HIV) proteins, 5, 12, 13 but its most potent stimulant is interferon gamma (IFN-γ).
14,15 IFN-γ is able to induce both the gene expression and enzymatic activity of IDO-1. 16, 17 Recently, an IDO related enzyme, IDO-2, was identifi ed. 7, 6 The encoding genes for IDO-1 and IDO-2 are located next to each other and IDO-2 possesses similar structural and enzymatic activities as IDO-1. However, IDO-2 differs in its expression pattern and signalling pathway and is preferentially inhibited by D-1-methyl-tryptophan. 7, 6 As tryptophan proceeds along the kynurenine pathway to achieve the fi nal product, nicotinamide adenosine dinucleotide (NAD), kynurenine is the fi rst stable intermediate formed. Subsequently, several neuroactive intermediates are generated. These comprise the free-radical generator, 3-hydroxyanthranilic acid, 18 the excitotoxin and N-methyl-D-aspartic acid (NMDA) receptor agonist, quinolinic acid, 19 the NMDA antagonist, kynurenic acid, 20 and the neuroprotectant, picolinic acid. 21 During an immune response, the release of IFN-γ by activated T cells and leukocytes leads to an accelerated and sustained degradation of tryptophan. This signifi cance was fi rst speculated to be a defence mechanism that starved tumour cells, pathogens and parasites of tryptophan. 22, 23 However, with the discovery that IDO-1 activity was necessary for the preservation of allogenic fetuses in mice, further in vitro research found that tryptophan depletion had an anti-proliferative and apoptotic effect on T cells. [24] [25] [26] In particular, the general control non-derepressible-2 (GCN2) kinase was identifi ed as a key mediator in IDO-1 induced tryptophan depletion immunosuppression. 27 The activation of GCN2 triggers a stress-response program that can result in cell-cycle arrest, differentiation, adaptation or apoptosis. [28] [29] [30] Furthermore, some of the kynurenines, such as quinolinic acid and 3-hydroxyanthranilic acid, can also effectively suppress T cell proliferation. 31 This inhibition appears to selectively target immune cells undergoing activation 32 and these kynurenines may act in concert to produce an additive effect. 33 Lastly, the production of the excitotoxin quinolinic acid is often signifi cantly increased following infl ammation and resulting immune activation. 34 To date, the kynurenine pathway has been implicated in a variety of diseases and disorders, including acquired immune defi ciency syndrome (AIDS) dementia complex, Alzheimer's disease (AD), schizophrenia, Huntington's disease, amyotrophic lateral sclerosis (ALS) and neoplasia, [35] [36] [37] [38] [39] [40] [41] [42] [43] and numerous studies have measured the levels of tryptophan and kynurenines under those conditions. Signifi cant imbalances in tryptophan and its metabolites were frequently observed, which when brought back within normal ranges, often resulted in alleviation of symptoms. This review brings together most of these studies to provide a better idea of the expected differences in tryptophan and kynurenine levels in the serum, cerebrospinal fl uid (CSF) and brain between disease and healthy states. at higher concentrations, at the glutamate site of the NMDA receptors and also on the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. 46 In addition, it also antagonizes the alpha 7 nicotinic acetylcholine receptors 47 and selectively activates a G-protein coupled receptor, GPR35. 48 Increases in brain kynurenic acid were fi rst observed to have sedative and anticonvulsant effects. 49 Later, it was found to be protective against brain ischemia. 50 The elevation in CSF kynurenic acid in schizophrenic patients also provided a new insight into the possible effect of kynurenic acid on the glutamatergic and dopaminergic systems, and its potential role in the pathogenesis of schizophrenia. 51, 52 Although it is argued that the physiological levels of kynurenic acid may fall below that which is necessary for glutamate receptor antagonism, at specifi c sites within synapses, those levels may be suffi cient. 53 This hypothesis is supported by the signifi cant reduction in glutamate release and extracellular levels of dopamine seen with kynurenic acid in rats in vivo. 54, 55 In addition, the use of kynurenine 3-hydroxylase inhibitor also led to a hyperactivity in dopamine neurons. 56 In a septic shock mouse model, kynurenic acid was able to signifi cantly decrease the release of tumour necrosis factor α (TNF-α), nitric oxide and high mobility group box 1 protein, a molecule likely to be involved in lipopolysaccharides mediated toxicity. 57, 58 Rather unexpectedly though, kynurenic acid inhibited the release of fi broblastic growth factor 1, a compound that supports growth and recovery of injured cells and enhances proliferation of glia cells. 59 However, this does not necessarily challenge the concept of kynurenic acid being neuroprotective but defi nitely warrants more investigation.
3-hydroxyanthranilic acid
3-hydroxyanthranilic acid can be derived either from the hydrolysis of 3-hydroxykyurenine or the oxidation of anthranilic acid (Fig. 1) . Besides playing a role in immunoregulation, [60] [61] [62] 3-hydroxyanthranilic acid is also a neurotoxin. Intracerebral injection of 3-hydroxyanthranilic acid leads to a decrease in choline acetyltransferase activity similar to those seen with quinolinic acid, but to a lesser extent. 21 In addition, it is a free radical (superoxide and hydrogen peroxide) generator in the presence of copper. 18 However, 3-hydroxyanthranilic acid can also act as an antioxidant, scavenging peroxyl radicals more effectively than equimolar concentrations of either ascorbic acid or Trolox (a water soluble analogue of vitamin E). 63 In murine macrophages, 3-hydroxyanthranilic acid at sub-millimolar concentrations can inhibit the activation of nuclear factor κB and likewise, the expression and activity of inducible nitric oxide synthase (iNOS). 64 iNOS catalyses the formation of NO, which is strongly correlated with antimicrobial and antitumoral activities in mouse macrophages. 65 Following along the lines of tumoregenesis, non-toxic concentrations of 3-hydroxyanthranilic acid has no effect on T cell receptor triggered CD8 + T lymphocyte proliferation, but greatly inhibits that induced by antigen-independent cytokine (particularly interleukin (IL)-2, IL-7 and IL-15) stimulation. 66 Thus, in the context of cancer, tumour cells could severely arrest CD8 + T cell proliferation by driving cytokine production without effectively triggering T cell receptor response. 66 Furthermore, 3-hydroxyanthranilic acid exerts a selective apoptotic effect on murine thymocytes and T helper 1 (Thl) cells via the activation of caspase-8 and release of cytochrome c from mitochondria, but independent of the Fas pathway. 61 This action occurs at concentrations well below those resulting in neurotoxicity or apoptosis of macrophages and could represent an important role in peripheral immunoregulation. 61 Adding to this, following antigen stimulation of myelin basic protein Acl-11 T cell receptor transgenic CD4 + T cells, 3-hydroxyanthranilic acid was associated with a Gi/S phase arrest in CD4
+ T cells and a cytokine profi le shift in favour of Th2 cells. 67 This fi nding has important implications in the treatment of multiple sclerosis (MS). 67 
Picolinic acid
Picolinic acid, a monocarboxylic acid, is an endogenous neuroprotectant and a natural iron and zinc chelator. 21 It controls cellular growth and has antitumoral, antifungal and antiviral activities. In vitro, picolinic acid arrests normal cells in G 1 phase, possibly through the interactions with NAD + as the inhibition can be overcome by nicotinamide. 68 Recently, the characterization of the kynurenine pathway in human primary adult neurons and SK-N-SH neuroblastoma cell line found the former capable of synthesizing picolinic acid but not the latter. 69 This variation in kynurenine pathway activation in neuroblastoma cells may provide a key to understanding tumour persistence and associated neurotoxicity.
In vivo, the antitumoral effect of picolinic acid was observed when treatment in mice inoculated with MBL-2 lymphoma cells altered their ribosomal ribonucleic acid (RNA) metabolism, augmenting the cytotoxic and tumoricidal activities of macrophages, resulting in increased survival rate. 70, 71 As an antifungal, picolinic acid acts synergistically with IFN-γ to amplify the inhibitory effect of neutrophils, inhibiting Candida albicans growth in vitro and in vivo. 72, 73 Although the mechanism of this co-stimulatory effect is unclear, it is known to be vulnerable to IL-4 suppression. 74 In mouse, the synergy with IFN-γ is further extended to include NOS and TNF-α gene expression. 75, 76 At relatively high concentrations (1.5-3 mM), picolinic acid exerts antiviral, cytotoxic and apoptotic effects on HIV-1 and human herpes simplex virus-2, 77 which is likely to be associated with an up-regulation in macrophage infl ammatory protein (MIP)-1α and MIP-1β messenger RNA (mRNA) expression, as both compounds inhibit HIV-1 infection. [78] [79] [80] Interestingly, this stimulatory effect on MlP-lα and β is antagonized by IFN-γ. 81 The complex interplay between picolinic acid and IFN-γ highlights the importance of these molecules on the regulation of macrophage activities and perhaps, the infl ammatory response. 81 Like kynurenic acid, picolinic acid blocks quinolinic acid induced neurotoxicity, but not the neuroexcitatory component. 21, 82 Compared to kynurenic acid though, picolinic acid is less potent and appears to act via a different mechanism, attenuating calcium dependent glutamate release and/or chelating endogenous zinc. 83, 84, 85 This lower potency of picolinic acid may also be partly explained by the weak stimulatory action it has on glutamate release from the striatum. 84 
Quinolinic acid
Quinolinic acid is a heterocyclic amino acid that selectively activates the neuronal NMDA subtype of glutamate receptors. 19 Within the brain, quinolinic acid concentrations are normally lower compared to blood and systemic tissues as tryptophan is metabolized to 5-hydroxytryptamine rather than to formylkynurenine. 86 However, during an immune response, either systemic or central, IDO-1 activity and levels of quinolinic acid rise dramatically, the signifi cance of which is still obscure. [87] [88] [89] Under infl ammatory conditions in the brain, infi ltrating macrophages, microglia and dendritic cells are major sources of quinolinic acid production. 90, 91, 92 Astrocytes, in contrast, are incapable of synthesizing quinolinic acid due to the absence of the enzyme, kynurenine hydroxylase. 93 Rather, both astrocytes and neurons, 9 being neuroprotective, uptake quinolinic acid and catabolize it to NAD. However, this catabolic system is easily saturated in the presence of high amounts of quinolinic acid, produced under pathological conditions, resulting in the toxic accumulation of quinolinic acid within the cells. 94 As an endogenous molecule of the mammalian CNS, the immune and neurotoxic properties of quinolinic acid are of special interest. 95 In vitro, the synthesis of quinolinic acid by CD8 − " dendritic cells induced apoptosis in Thl target cells; 96 and quinolinic acid can also selectively inhibit the proliferation of CD4 + and CD8 + T lymphocytes and natural killer cells undergoing activation, the effect of which is amplifi ed in the absence of tryptophan. 32 In direct intracerebral administration and neuronal cell cultures, quinolinic acid led to neuronal death. 97, 98 Similarly, the chronic exposure to sub-micromolar concentrations of quinolinic acid on neurons produced an adverse effect and the converse was true too. 99, 98 In vivo, injection of quinolinic acid into discrete regions of the rat brain caused axon-sparing lesions similar to those produced by kainic and ibotenic acid. 97 Several studies have already provided strong evidence suggesting that quinolinic acid plays a signifi cant pathological role in the development of neurodegenerative disorders, such as Huntington's disease (HD), 99 AD 100, 101, 102 and AIDS dementia complex.
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The Kynurenine Pathway in Disease States
Under various pathological conditions, an accelerated degradation of tryptophan with an accompanying increase in kynurenines is often observed in the serum, CSF and/or brain tissue (Tables 1, 2 and 3) . Moreover, the breakdown of tryptophan via the kynurenine pathway is often routed preferentially towards the production of quinolinic acid. The pathologies associated with the up-regulation of the kynurenine pathway include infectious diseases (e.g. HIV), neurological disorders (e.g. AD, HD and ALS), affective disorders (e.g. schizophrenia, depression and anxiety), autoimmune diseases (e.g. MS and rheumatoid arthritis), peripheral conditions (e.g. cardiovascular disease) and malignancy (e.g. haematological neoplasia and colorectal cancer). However, signifi cant elevations in tryptophan levels in lung and breast cancer have also been reported. 106 We also observed an increase in tryptophan levels ALS patients' samples (unpublished). At this stage, we speculate that this phenomenon might be associated with either a disturbance in albumin binding of tryptophan, an over-compensatory response to decreased tryptophan concentrations in the brain and/or a malfunctioning in the L-type amino acid transporter at the blood brain barrier in ALS. The elevation in tryptophan notwithstanding, ALS patients still exhibited a larger kynurenine/ tryptophan (K/T) ratio, an index for IDO activity, than control subjects due to a signifi cant concomitant rise in kynurenine.
The enhanced degradation of tryptophan and higher K/T ratio are also often associated with advanced stages of disease, more severe symptoms or a fatal outcome. 107 108,109 However, it is important to note that a progressive increased in tryptophan catabolism is part of the "normal" ageing process. 110 Nonetheless, the degree of tryptophan depletion is still far more substantial in neurodegenerative disorders compared to normal ageing and most of the studies on pathological conditions were performed using age matched control subjects. 111, 100 In some studies, neopterin concentrations were also measured. Neopterin is a marker for immune activation and show a correlation with the K/T ratio and kynurenine, and inversely with tryptophan. 112, 113, 87 This suggests an increase in endogenous IFN-γ production and an up-regulation in the kynurenine pathway. Indeed, HIV patients exhibit a 10-fold increase in IFN-γ through direct measurements. 114 When HIV patients are treated with highly active antiretroviral therapy (HAART) or antiretroviral treatment (ART), which signifi cantly decreases immune activation through reduction in viral load, a repletion in tryptophan and reduction in kynurenine and quinolinic acid often follows. 115, 116 It is interesting to note that the alteration in tryptophan levels occurred in the absence of any dietary modifi cation and that changes in K/T ratio correlated strongly with HIV mRNA and CD4 + T cell count. 116 The most important consequences of dramatic decline in tryptophan, thus, are likely to be immunosuppression and immunodeficiency, particularly evident in HIV infection, but also in autoimmune diseases and cancer. Other effects include weight loss, mood disturbances and cognitive impairment. 117, 118 In anorexia nervosa, underweight anorexic patients had lower tryptophan levels which rose with weight normalization. 117 The association of tryptophan levels and the development of cachexia and weight loss are also evident in neoplasia. 119, 120 This could be associated with the release of proinfl ammatory cytokines. TNF-α, for instance, is a known cachexia, featuring prominently in muscle pathophysiology. 121 The heightened catabolism of tryptophan via the kynurenine pathway may also divert this essential amino acid away from protein synthesis, thus, contributing to weight loss and muscle wasting. 119 Tryptophan also acts as a precursor for the synthesis of serotonin, which has a broad spectrum of action, two of which are in mood and cognitive functioning. 118, 122 Imbalances in kynurenines and significant decline in 5-hydroxyindoleacetic acid (5-HIAA), a serotonin metabolite, have been reported in major depression, MS and cardiovascular disease, among others. 123, 124, 125 However, the activation of the immune response is also postulated as a cause of depression 126, 127 and a strong association exists between infl ammatory diseases and depression. 128, 129 In normal subjects, the deliberate depletion of tryptophan selectively impaired long-term memory consolidation, 130 opposed to the results observed with the administration of selective serotonin reuptake inhibitors. 131 In AD and HD patients, the K/T ratio was also inversely correlated with cognitive performance; 132, 133 and in HIV-1 patients, treatment with HAART, which elevates tryptophan levels, markedly improved cognitive function. 134, 135 
Potential Treatments Involving the Kynurenine Pathway
The involvement of the kynurenine pathway in a wide range of diseases suggests that research on treatment strategies targeting the kynurenine pathway (Fig. 2) may provide an alternative means of treatment or as a complement to what is already available.
Niacin supplementation
One of the consequences of accelerated degradation and depletion of tryptophan in the body is the suppression of T cell proliferation, 136 which compromises the body's immunity. Repletion of tryptophan could lead to improve immune response but may also inadvertently cause an increase in neurotoxins. Niacin supplementation, however, provides an indirect way to increase tryptophan and act as a feedback mechanism to suppress IDO-1 activity. 137 In clinical studies, dietary supplementation of niacin to HIV-1 patients was associated with higher CD4 counts and improved survival rates. 138, 139 
IDO inhibitors
The suppression of IDO-1 activity has been targeted directly in cancer research. Using transgenic mouse model of breast cancer, IDO-1 inhibitors, 1-methyl-DL-tryptophan and methyl-thiohydantointryptophan, were able to potentiate the effi cacy of chemotherapy drugs, promoting tumour regression without increasing the side effects. 140 The discovery of the preferential inhibition by D-l-methyltryptophan on IDO-2 could also provide the key to understanding the mechanism behind the antitumoral action of 1-methyl-tryptophan and in designing future IDO inhibitors. 7 
Kynurenine analogues
Another approach to modifying the kynurenine pathway is to skew the balance of kynurenines towards neuroprotection and away from neurotoxicity. Currently, there are several therapeutic agents, either already on the market or undergoing clinical trials, which are either analogues of neuroprotective kynurenines or act to inhibit the production of quinolinic acid. They include 4-chlorokynurenine, laquinimod, lefl unomide, tranilast, nicotinylalanine, meta-nitrobenzoylalanine and Ro61-8048.
7-chlorokynurenate, a synthetic derivative of kynurenic acid, attenuates the neurotoxic effect of quinolinic acid through blockade of the glycine modulatory site of the NMDA receptor. 141, 142 However, 7-chlorokynurenate crosses the blood brain barrier with great diffi culty. 143 4-chlorokynurenine, a precursor of 7-chlorokynurenate, on the other hand, is able to overcome this obstacle. 144 When administered together with quinolinic acid in vivo, 4-chlorokynurenine was converted into the active 7-chlorokynurenate successfully, providing neuroprotection. 145, 146 Laquinimod (ABR-215062), a novel synthetic quinoline, has demonstrated immunomodulatory properties without immunosuppression in preclinical trials. [147] [148] [149] In MS animal model, experimental autoimmune encephalomyelitis (EAE), laquinimod delayed disease progression, inhibited infi ltration of CD4 + T cells and macrophages into the CNS and modulated the immune response in favour of Th2/Th3 cytokines IL-4, IL-10 and transforming growth factor (TGF-P). 150 Furthermore, in patients with relapsing MS, treatment with laquinimod successfully reduced the development of active lesions. 151 Lefl unomide (Avara ® ), an immunosuppressive and anti-infl ammatory prodrug is converted into terfl unomide in vivo (A771126). Terfl unomide is an inhibitor of mitochondrial dihydroorotate dehydrogenase, an essential enzyme for de novo pyrimidine synthesis. 152 In 1998, the Food and Drug Administration (FDA, U.S.A.) approved leflunomide for the treatment of rheumatoid arthritis. Furthermore, in a recent phase II trial with MS patients, terfl unomide proved well tolerated and effective in reducing active lesions. 153 Tranilast (Rizaben ® ), a synthetic anthranilic acid derivative drug, has the ability to inhibit the release of chemical mediators, TGF-É¿ and suppress angiogenesis. 154, 155 Tranilast has been effective against many diseases, such as allergic rhinitis, atopic dermatitis and bronchial asthma. Recently, when tested against EAE, tranilast inhibited the actions of Thl cells while enhancing those of Th2 cells, an action similar to that of natural tryptophan catabolites, 3-hydroxyanthranilic acid and 3-hydroxykynurenic acid. 67 Finally, kynurenine hydroxylase inhibitors are also effective in diverting the kynurenine pathway away from the synthesis of quinolinic acid towards that of kynurenic acid. These compounds include nicotinylalanine, meta-nitrobenzoylalanine and Ro61-8048. 156 Nicotinylalanine, an analogue of kynurenine, protects the brain from induced seizures 157, 158 and quinolinic acid induced striatal damage in the rat. 159 With meta-nitrobenzoylalanine, sedation and anticonvulsant effects were achieved in rats, 160 while reduced neuronal loss from brain ischemia were seen in gerbils. 50 In immune activated mice, meta-nitronemzoylalanine also signifi cantly decreased quinolinic acid production in the blood and brain. 161 With Ro61-8048, there is an additional benefit of reducing glutamate levels in the extracellular spaces of the basal ganglia in rats, while maintaining the learning and memory process. 162 In EAE rats, administration of Ro61-8048 significantly reduced the neurotoxic levels of 3-hydroxykynurenine and quinolinic acid in the CNS; 163 and in a cerebral malaria mouse model, it signifi cantly increased the neuroprotective levels of picolinic acid, prevented the development of neurological symptoms and prolonged survival by threefold. 164 Like meta-nitrobenzoylalanine, Ro61-8048 too decreased neuronal loss due to brain ischemia.
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Conclusion
The kynurenine pathway is an effective mechanism in modulating the immune response and in inducing immune tolerance. This is achieved by accelerating the degradation of tryptophan and the generation of kynurenines. The metabolites of the pathway, with their different inherent properties, can also synergize or antagonize the effects of one another. By measuring the levels of tryptophan, kynurenines and the K/T ratio under various pathological conditions, the degree of immune activation and the relationship between the kynurenine pathway and disease states may be gleaned. However, much research is still needed to fully understand the complex interaction between tryptophan, IDO and kynurenines among themselves and within the CNS and in the periphery. With the seemingly prevalent involvement of the kynurenine pathway in a wide range of different diseases and disorders, the knowledge gained from research focusing on the kynurenine pathway may be translated into designing novel and more effective treatment strategies.
